Deregulation of stemness and senescence genes in bone marrow mesenchymal stem cells of multiple myeloma: implications for therapeutic approaches
Blood Research · 2026-12 · 61 (1)
DOI: 10.1007/s44313-026-00128-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Research, online erschienen am 07.05.2026. Verfasst von Fatemeh Soleymani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Faculty of Medical Sciences, Tarbiat Modares University.
Abstract (Originalsprache)
Purpose
Multiple myeloma (MM) is a hematologic malignancy associated with a poor prognosis. MM-derived mesenchymal stromal cells (MM-MSCs) contribute to disease progression by creating a supportive stromal microenvironment for malignant cells. Elucidating transcriptomic alterations in MSCs may therefore facilitate the development of novel therapeutic strategies for treatment-resistant MM.
Methods
Total RNA was extracted from cultured MSCs isolated from bone marrow aspirates of patients with MM and normal donors (ND-MSCs). Expression of stemness markers ( NANOG , OCT4 ) and senescence-associated genes ( P16 , P21 , IL-6 , IL-8 ) was analyzed using reverse transcription-quantitative polymerase chain reaction. Cellular senescence was assessed by senescence-associated β-galactosidase (SA-β-gal) staining.
Results
Compared with ND-MSCs, MM-MSCs demonstrated a higher percentage of SA-β-gal-positive cells. Gene expression analysis showed upregulation of P21 and IL-6 in MM-MSCs, whereas NANOG and OCT4 were significantly downregulated. Notably, this downregulation was consistent with analysis of a publicly available RNA sequencing dataset, supporting the validity of our findings.
Conclusions
Consistent with previous reports of increased senescence, our findings demonstrate significant downregulation of stemness-related genes ( NANOG , OCT4 ) in MSCs from newly diagnosed, untreated patients with MM. This concurrent dysregulation of stemness and increased senescent phenotype may contribute to the pathogenicity of the tumor microenvironment and represents a potential target for therapeutic intervention. Clinical Trial Registration Not applicable. This study did not involve a clinical trial. Graphical Abstract
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
- Department of Medical Oncology and Hematology, Iran University, Tehran, Iran.
- Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran. mahmadvand@sina.tums.ac.ir.
Förderung
- Faculty of Medical Sciences, Tarbiat Modares University
Zitieren
APA
Soleymani, F., Kavousi, S., Khodakarim, N., & Ahmadvand, M. (2026). Deregulation of stemness and senescence genes in bone marrow mesenchymal stem cells of multiple myeloma: implications for therapeutic approaches. Blood Research, 61(1). https://doi.org/10.1007/s44313-026-00128-3
Vancouver
Soleymani F, Kavousi S, Khodakarim N, Ahmadvand M. Deregulation of stemness and senescence genes in bone marrow mesenchymal stem cells of multiple myeloma: implications for therapeutic approaches. Blood Research. 2026;61(1). doi:10.1007/s44313-026-00128-3
BibTeX
@article{Soleymani2026,
author = {Soleymani, Fatemeh and Kavousi, Saeideh and Khodakarim, Nastaran and Ahmadvand, Mohammad},
title = {Deregulation of stemness and senescence genes in bone marrow mesenchymal stem cells of multiple myeloma: implications for therapeutic approaches},
journal = {Blood Research},
year = {2026},
volume = {61},
number = {1},
doi = {10.1007/s44313-026-00128-3}
}
EUVIMED